Once-daily OROS® methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 16, Issue 3, 2006, Pages 351-356

  McGough, James J ^a,h   McBurnett, Keith ^b   Bukstein, Oscar ^c   Wilens, Timothy E ^d   Greenhill, Laurence ^e   Lerner, Marc ^f   Stein, Mark ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; OROS;

ADOLESCENT; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CELLULITIS; CHILD PSYCHIATRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

ADOLESCENT; ANOREXIA; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG ADMINISTRATION SCHEDULE; HEADACHE; HUMANS; METHYLPHENIDATE; SLEEP INITIATION AND MAINTENANCE DISORDERS; WEIGHT LOSS;

EID: 33745146853     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2006.16.351     Document Type: Article

References (25)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington (DC), American Psychiatric Association, 1994.
2. Barkley RA: Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:(Suppl 12): 10-15, 2002.
3. Barkley RA, Fischer M, Edelbrock CS, Smallish L: The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year, prospective, follow-up study. J Am Acad Child Adolesc Psychiatry 29:546-557, 1990a.
4. Barkley RA, McMurray MB, Edelbrock CS, Robbins K: Side effects of methylphenidate in children with attention-deficit/hyperactivity disorder: A systemic, placebo-controlled evaluation. Pediatrics 86:184-192, 1990b.
5. Biederman J: New-generation long-acting stimulants for the treatment of attention-deficit/hyperactivity disorder. Medscape Psychiatry and Mental Health (serial online). New York, WebMD Medscape Health Network, Vol. 2, 2003.
6. Biederman J: Practical consideration in stimulant drug selection for the attention-deficit/hyperactivity disorder patient: Efficacy, potency, and titration. Todays Ther Trends 20:311-318, 2002.
7. Biederman J, Mick E, Faraone SV: Age-dependent decline of symptoms of attention-deficit/hyperactivity disorder: Impact of remission definition and symptom type. Am J Psychiatry 157:816-818, 2000.
8. Evans SW, Pelham WE, Smith BH, Bukstein O, Gnagy EM, Greiner AR, Altenderfer L, Baron-Myak C: Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp Clin Psychopharmacol 9:163-175, 2001.
9. Greenhill LL, Halperin JM, Abikoff H: Stimulant medications. J Am Acad Child Adolesc Psychiatry 38:503-512, 1999.
10. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S: Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41(Suppl 2):26S-49S, 2002.
11. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T: Impairment and deportment responses to different methylphenidate doses in children with ADHD: The MTA titration trial. J Am Acad Child Adolesc Psychiatry 40:180-187, 2001.
12. Hart EL, Lahey BB, Loeber R, Applegate B, Frick PJ: Developmental changes in attention-deficit/hyperactivity disorder in boys: A four-year longitudinal study. J Abnorm Child Psychol 23:729-749, 1995.
13. Jensen PS, Kettle L, Roper MT, Sloan MT, Dulcan MK, Hoven C, Bird HR, Bauermeister JJ, Payne JD: Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry 38:797-804, 1999.
14. Klorman R, Brumaghim JT, Fitzpatrick PA, Borgstedt AD: Clinical effects of a controlled trial of methylphenidate on adolescents with attention-deficit disorder. J Am Acad Child Adolesc Psychiatry 29:702-709, 1990.
15. Lambert NM, Hartsough CS, Sassone D, Sandoval J: Persistence of hyperactivity symptoms from childhood to adolescence and associated outcomes. Am J Orthopsychiatry 57:22-32, 1987.
16. Mannuzza S, Klein RG, Bessler A, Malloy P, Hynes ME: Educational and occupational outcome of hyperactive boys grown up. J Am Acad Child Adolesc Psychiatry 36:1222-1227, 1997.
17. Murphy KR, Barkley RA, Bush T: Young adults with attention-deficit/ hyperactivity disorder: Subtype differences in comorbidity, educational, and clinical history. J Nerv Ment Dis 190:147-157, 2002.
18. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107:E105, 2001.
19. Perrin JM, Stein MT, Amler RW, Blondis TA, Feldman HM, Meyer BP, Shaywitz BA, Wolraich ML: Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108:1033-1044, 2001.
20. Smith BH, Waschbusch DA, Willoughby MT, Evans S: The efficacy, safety, and practicality of treatments for adolescents with attention-deficit/ hyperactivity disorder (ADHD). Clin Child Fam Psychol Rev 3:243-267, 2000.
21. Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S: Pharmacotherapy of attention-deficit/hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35: 409-432, 1996.
22. Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A: Attention-deficit/hyperactivity disorder: Increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 42:1415-1423, 2003.
23. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Holland D, Casat C, Denisco MJ, Halstead P, Lynch J, Zimmerman BA, Gu J, Cooper KM, Bowen DL: A multisite, controlled trial of OROS methylphenidate (Concerta) in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Ped Adolesc Med 160:82-90, 2006.
24. Wilens T, Pelham W, Stein M, Conners K, Abikoff H, Atkins M, August G, Grennhill L, McBurnett K, Palumbo D, Swanson J, Wolraich M: ADHD treatment with once-daily OROS methylphenidate: Interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 42:424-433, 2003.
25. Wolraich M, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G: Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 108:883-892, 2001.